Results from a Phase I study suggest that histone deacetylase (HDAC) inhibitors may boost the efficacy of epirubicin (Ellence, Pfizer) in advanced sarcoma patients (Ann Oncol 2016 Feb 21. [Epub ahead of print]). The findings showed that 57% of the 40 study participants, 20 of whom had advanced sarcoma, experienced either partial response or stable disease with the combination treatment, after not responding to prior anthracycline treatment.
The HDAC inhibitors, vorinostat (Zolinza,